Search is Powered by Google
Cancer / Oncology News

Too Many Gene Copies Stimulate Tumor Cell Growth

Main Category: Cancer / Oncology
Also Included In: Genetics
Article Date: 09 Apr 2008 - 5:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

New data, generated by Peter Lichter and colleagues, at the German Cancer Research Center, Heidelberg, have characterized a molecular pathway underlying low-grade forms of a type of brain tumor known as an astrocytoma. The authors therefore suggest that therapeutics targeting this pathway might provide a new approach to treating individuals with low-grade atrocytomas.

Analysis of the DNA of astrocytomas from a large number of children revealed that the most common genetic mutation was the duplication of a region of DNA containing the BRAF gene. Tumors with this genetic mutation showed signs of increased BRAF protein activity. Consistent with the idea that increased BRAF activity had a role in the development of the tumors, mutations in the BRAF gene that caused increased BRAF protein activity were detected in tumors that did not exhibit duplication of the region of DNA containing the BRAF gene. As pharmacologic and genetic silencing of the BRAF signaling pathway and the BRAF gene, respectively, prevented tumor cells from low-grade gliomas growing in culture, it was suggested that inhibiting the signaling pathway downstream of BRAF might be beneficial for individuals with low-grade atrocytomas.

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

TITLE: BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas

AUTHOR CONTACT:

Peter Lichter
German Cancer Research Center, Heidelberg, Germany.

View the PDF of this article at: http://www.the-jci.org/article.php?id=33656

Source:
Karen Honey
Journal of Clinical Investigation

Ad Banner - the most access to the best resources


Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar

Sign up to receive newsletters / news alerts
MedReader RSS Reader


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating Prostate Cancer Symptoms image Treating Prostate Cancer Symptoms

Many men will have advanced prostate cancer without any noticeable symptoms. Treatment for these patients is a bit different than for other patients with prostate cancer. Learn about these differences...

View more videos...